{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:37:12Z","timestamp":1792035432856,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013631","name":"Montana Water Center, Montana State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.yebeh.2022.108994","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:59:55Z","timestamp":1669910395000},"page":"108994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (&lt;5 years) with Dravet syndrome: A critical period for early neurodevelopment"],"prefix":"10.1016","volume":"138","author":[{"given":"Kim I.","family":"Bishop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Isquith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A.","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Knupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-2174","authenticated-orcid":false,"given":"Ingrid E.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8988","authenticated-orcid":false,"given":"Joseph","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Helen Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Farfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-3327","authenticated-orcid":false,"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-2862","authenticated-orcid":false,"given":"Arnold R.","family":"Gammaitoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108994_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107079","article-title":"Intellectual functioning and behavior in Dravet syndrome: a systematic review","volume":"108","author":"Jansson","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108994_b0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/epi.12652","article-title":"Dravet syndrome\u2013from epileptic encephalopathy to channelopathy","volume":"55","author":"Brunklaus","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/320609","article-title":"De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy","volume":"68","author":"Claes","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108994_b0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/09297049.2014.959480","article-title":"Cognitive characterization of children with Dravet syndrome: a neurodevelopmental perspective","volume":"21","author":"Acha","year":"2015","journal-title":"Child Neuropsychol"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0025","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/epi.16844","article-title":"Deconstructing Dravet syndrome neurocognitive development: A scoping review","volume":"62","author":"Bertuccelli","year":"2021","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2022.108994_b0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eplepsyres.2011.03.005","article-title":"Neuropsychological development in children with Dravet syndrome","volume":"95","author":"Chieffo","year":"2011","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12160-009-9097-4","article-title":"Executive functioning: overview, assessment, and research issues for non-neuropsychologists","volume":"37","author":"Suchy","year":"2009","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.yebeh.2022.108994_b0040","series-title":"Executive function in education: From theory to practice","first-page":"57","article-title":"Executive capacities from a developmental perspective","author":"Bernstein","year":"2018"},{"key":"10.1016\/j.yebeh.2022.108994_b0045","series-title":"Pediatric neuropsychology: research, theory, and practice","first-page":"473","article-title":"Dysexecutive syndrome","author":"Gioia","year":"2022"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1037\/0033-2909.134.1.31","article-title":"Executive function in preschoolers: a review using an integrative framework","volume":"134","author":"Garon","year":"2008","journal-title":"Psychol Bull"},{"key":"10.1016\/j.yebeh.2022.108994_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2016.06.006","article-title":"Executive function and health-related quality of life in pediatric epilepsy","volume":"62","author":"Schraegle","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mrdd.20075","article-title":"Assessment of executive function in preschool-aged children","volume":"11","author":"Isquith","year":"2005","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1469-8749.2007.00412.x","article-title":"Executive functioning in childhood epilepsy: parent-report and cognitive assessment","volume":"49","author":"Parrish","year":"2007","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108994_b0070","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1017\/S1355617702801308","article-title":"Executive functions in children with frontal and temporal lobe epilepsy","volume":"8","author":"Culhane-Shelburne","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0075","first-page":"404","article-title":"Assessment of executive functioning in childhood epilepsy: the Tower of London and BRIEF","volume":"18","author":"MacAllister","year":"2012","journal-title":"Child Neuropsychol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/09297049.2014.967670","article-title":"Cognitive estimations as a measure of executive dysfunction in childhood epilepsy","volume":"22","author":"MacAllister","year":"2016","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2022.108994_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jsp.2018.12.004","article-title":"Test use and assessment practices of school psychologists in the United States: Findings from the 2017 National Survey","volume":"72","author":"Benson","year":"2019","journal-title":"J Sch Psychol"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2022.108994_b0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2016.08.018","article-title":"The role of executive functioning in quality of life in pediatric intractable epilepsy","volume":"64","author":"Love","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09297040600611320","article-title":"Frequency of scale elevations and factor structure of the Behavior Rating Inventory of Executive Function (BRIEF) in children and adolescents with intractable epilepsy","volume":"12","author":"Slick","year":"2006","journal-title":"Child Neuropsychol"},{"issue":"10216","key":"10.1016\/j.yebeh.2022.108994_b0100","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108994_b0105","unstructured":"Bishop KI, Gioia GA, Isquith PK, Gammaitoni AR, Farfel G, Galer BS, et al. Improved everyday executive function with Fintepla\u00ae (fenfluramine HCI oral solution): results from a phase 3 study in children and young adults with Dravet syndrome [poster]. American Epilepsy Society Annual Meeting, November 30-December 4, 2018, New Orleans, LA."},{"key":"10.1016\/j.yebeh.2022.108994_b0110","unstructured":"Bishop KI, Isquith PK, Roth RM, Gioia GA, Knupp KG, Sullivan J, et al. Adults with Lennox-Gastaut Syndrome have improved everyday executive functioning with fenfluramine (Fintepla\u00ae)[poster]. European Epilepsy Congress (EEC), Geneva, Switzerland, July 9-13, 2022."},{"key":"10.1016\/j.yebeh.2022.108994_b0115","doi-asserted-by":"crossref","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Sullivan J, et al. FINTEPLA (fenfluramine) treatment improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis from a phase 3 clinical trial [oral presentation]. American Academy of Neurology Annual Meeting, April 17-22, 2021, Virtual meeting.","DOI":"10.1055\/s-0041-1739606"},{"key":"10.1016\/j.yebeh.2022.108994_b0120","doi-asserted-by":"crossref","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Sullivan J, Nabbout R, et al. Fenfluramine (Fintepla\u00ae) treatment improves everyday executive functioning in patients with Lennox-Gastaut Syndrome: analysis from a phase 3 clinical trial [poster]. American Academy of Neurology Annual Meeting, Seattle, WA, April 2-7, 2022.","DOI":"10.1212\/WNL.98.18_supplement.3017"},{"key":"10.1016\/j.yebeh.2022.108994_b0125","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Sullivan J, et al. Treatment dose is associated with improvement in everyday executive functioning in preschool children with Dravet Syndrome: analyses from two pooled phase 3 clinical studies [poster]. European Paediatric Neurology Society (EPNS), April 28\u2014May 2, 2022."},{"key":"10.1016\/j.yebeh.2022.108994_b0130","doi-asserted-by":"crossref","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Sullivan J, et al. Fenfluramine (Fintepla\u00ae) treatment improves everyday executive functioning in preschool children with Dravet syndrome: analysis from 2 pooled phase 3 clinical trials [poster]. American Epilepsy Society Annual Meeting, December 3-7, 2021, Chicago, IL.","DOI":"10.1055\/s-0041-1739606"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2022.108994_b0135","article-title":"Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children\/young adults with Dravet syndrome","volume":"121","author":"Bishop","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108994_b0140","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Sullivan J, Nabbout R, et al. Fenfluramine (Fintepla\u00ae) treatment improves everyday executive functioning in preschool children with Dravet Syndrome: analysis from 2 pooled phase 3 clinical trials [poster]. American Academy of Neurology (AAN), April 2-7, 2022, Seattle, WA."},{"key":"10.1016\/j.yebeh.2022.108994_b0145","series-title":"BRIEF\u00ae2 Behavior Rating Inventory of Executive Function\u00ae","author":"Gioia","year":"2015"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41398-021-01568-4","article-title":"D\u00e9j\u00e0-vu? Neural and behavioural effects of the 5-HT(4) receptor agonist, prucalopride, in a hippocampal-dependent memory task","volume":"11","author":"de Cates","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0155","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/cercor\/bhaa253","article-title":"Interplay between 5-HT4 receptors and GABAergic system within CA1 hippocampal synaptic plasticity","volume":"31","author":"Lecouflet","year":"2021","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.yebeh.2022.108994_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"16","key":"10.1016\/j.yebeh.2022.108994_b0165","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.3390\/ijms22168416","article-title":"An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies","volume":"22","author":"Martin","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.yebeh.2022.108994_b0170","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1017\/S0033291719002836","article-title":"A role for 5-HT(4) receptors in human learning and memory","volume":"50","author":"Murphy","year":"2020","journal-title":"Psychol Med"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108994_b0175","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1076\/chin.8.2.71.8724","article-title":"Assessment and development of executive function (EF) during childhood","volume":"8","author":"Anderson","year":"2002","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.yebeh.2022.108994_b0185","article-title":"The development of executive function in childhood","author":"Zelazo","year":"2008","journal-title":"Front Psychol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.semperi.2007.12.009","article-title":"Cognitive and educational deficits in children born extremely preterm","volume":"32","author":"Anderson","year":"2008","journal-title":"Semin Perinatol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0195","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects","volume":"57","author":"Boyd","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2022.108994_b0205","unstructured":"Boyd B, Smith S, Farfel G, Morrison G. A phase 1, single-dose, open-label pharmacokinetic study to investigate the drug-drug interaction potential of ZX008 (fenfluramine HCl oral solution) and cannabidiol [abstract]. Annual Meeting of the Child Neurology Society, October 23-26, 2019, Charlotte, NC."},{"key":"10.1016\/j.yebeh.2022.108994_b0210","series-title":"BRIEF\u00ae-P: Behavior Rating Inventory of Executive Function\u00ae\u2013Preschool Version Professional Manual","author":"Gioia","year":"2003"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108994_b0215","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/09297049.2017.1365829","article-title":"Utility of the behavior rating inventory of executive function - preschool version (BRIEF-P) in young children with epilepsy","volume":"24","author":"Maiman","year":"2018","journal-title":"Child Neuropsychol"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/arclin\/16.2.183","article-title":"Interpreting change on the WAIS-III\/WMS-III in clinical samples","volume":"16","author":"Iverson","year":"2001","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","article-title":"Clinical significance: a statistical approach to defining meaningful change in psychotherapy research","volume":"59","author":"Jacobson","year":"1991","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.yebeh.2022.108994_b0230","series-title":"Prediction in Forensic and Neuropsychology Sound Statistical Practices","first-page":"123","article-title":"Assessing reliable neuropsychological change","author":"Chelune","year":"2003"},{"key":"10.1016\/j.yebeh.2022.108994_b0235","series-title":"Encyclopedia of Clinical Neuropsychology","first-page":"2984","article-title":"Reliable change index","author":"Iverson","year":"2018"},{"key":"10.1016\/j.yebeh.2022.108994_b0240","series-title":"Pediatric Forensic Neuropsychology","first-page":"89","article-title":"Interpreting change on repeated neuropsychological assessments of children","author":"Iverson","year":"2012"},{"key":"10.1016\/j.yebeh.2022.108994_b0245","series-title":"Behavior Rating Inventory of Executive Function\u00ae (BRIEF\u00ae) Professional Manual","author":"Gioia","year":"2000"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0250","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2307\/2090408","article-title":"A new asymmetric measure of association for ordinal variables","volume":"27","author":"Somers","year":"1962","journal-title":"Am Sociol Rev"},{"key":"10.1016\/j.yebeh.2022.108994_b0255","series-title":"The two-dimensional case. Mathematical Methods of Statistics","first-page":"282","author":"Cram\u00e9r","year":"1946"},{"key":"10.1016\/j.yebeh.2022.108994_b0260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108994_b0270","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/09297049.2015.1054272","article-title":"Executive functioning profiles from the BRIEF across pediatric medical disorders: age and diagnosis factors","volume":"22","author":"Krivitzky","year":"2016","journal-title":"Child Neuropsychol"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.acn.2007.08.010","article-title":"Assessment of executive functions: review of instruments and identification of critical issues","volume":"23","author":"Chan","year":"2008","journal-title":"Arch Clin Neuropsychol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dr.2009.05.002","article-title":"Executive functions after age 5: changes and correlates","volume":"29","author":"Best","year":"2009","journal-title":"Dev Rev"},{"key":"10.1016\/j.yebeh.2022.108994_b0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108994_b0290","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108994_b0295","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0300","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108994_b0305","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"The International Consensus on Diagnosis and Management of Dravet Syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0310","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/brcg.1999.1117","article-title":"Executive functioning in preschool children: performance on A-not-B and other delayed response format tasks","volume":"41","author":"Espy","year":"1999","journal-title":"Brain Cogn"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0315","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1467-8624.2010.01499.x","article-title":"A developmental perspective on executive function","volume":"81","author":"Best","year":"2010","journal-title":"Child Dev"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0320","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2307\/1130325","article-title":"Expectation and anticipation of dynamic visual events by 3.5-month-old babies","volume":"59","author":"Haith","year":"1988","journal-title":"Child Dev"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0325","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2307\/1130099","article-title":"Development of the ability to use recall to guide action, as indicated by infants' performance on AB","volume":"56","author":"Diamond","year":"1985","journal-title":"Child Dev"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0330","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1207\/s15326942dn2601_3","article-title":"Executive function in preschool children: examination through everyday behavior","volume":"26","author":"Isquith","year":"2004","journal-title":"Dev Neuropsychol"},{"key":"10.1016\/j.yebeh.2022.108994_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106976","article-title":"Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective","volume":"185","author":"Jensen","year":"2022","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0340","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/dmcn.13613","article-title":"Is epilepsy the cause of comorbidities in Dravet syndrome?","volume":"60","author":"Gataullina","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108994_b0345","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1750-1172-8-176","article-title":"Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy","volume":"8","author":"Nabbout","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2022.108994_b0350","unstructured":"Faingold CL, Tupal S. The action of fenfluramine to prevent seizure-induced death in the DBA\/1 mouse SUDEP model is selectively blocked by an antagonist or enhanced by an agonist for the serotonin 5-HT4 receptor [abstract]. American Epilepsy Society Annual Meeting, December 6-10, 2019, Baltimore, MD."},{"key":"10.1016\/j.yebeh.2022.108994_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106777","article-title":"Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP","volume":"177","author":"Tupal","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108994_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107146","article-title":"Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients","volume":"110","author":"Montouris","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108994_b0365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.yebeh.2016.11.006","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108994_b0370","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17034","article-title":"Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.yebeh.2022.108994_b0375","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.0000000000006432","article-title":"Lorcaserin therapy for severe epilepsy of childhood onset: a case series","volume":"91","author":"Tolete","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108994_b0380","unstructured":"Reeder T, Martin P, Sourbron J, de Witte PA, Farfel GM, Galer BS, et al. Dual activity of fenfluramine (Fintepla\u00ae) as a serotonin receptor agonist and positive sigma-1 receptor modulator: implication for disease modification in developmental and epileptic encephalopathies [poster]. American Epilepsy Society Annual Meeting, December 3-7, 2021, Chicago, IL."},{"issue":"7","key":"10.1016\/j.yebeh.2022.108994_b0385","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2174\/138161212799436476","article-title":"Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases","volume":"18","author":"Niitsu","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0390","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/npp.2012.258","article-title":"Impact of serotonin (5-HT)2C receptors on executive control processes","volume":"38","author":"Pennanen","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.yebeh.2022.108994_b0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbb.2013.08.007","article-title":"The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition","volume":"123","author":"Logue","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.yebeh.2022.108994_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173243","article-title":"Impact of specific serotonin receptor modulation on behavioral flexibility","volume":"209","author":"Alvarez","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"issue":"24","key":"10.1016\/j.yebeh.2022.108994_b0405","doi-asserted-by":"crossref","first-page":"15187","DOI":"10.1021\/acs.jmedchem.0c01192","article-title":"Small molecules selectively targeting sigma-1 receptor for the treatment of neurological diseases","volume":"63","author":"Ye","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2022.108994_b0410","unstructured":"Ning Y, Reeder T, Noebels JL, Aiba I. Fenfluramine directly inhibits cortical spreading depolarization\u2014a pathophysiologic process linked to SUDEP [poster]. American Epilepsy Society Annual Meeting, December 3-7, 2021, Chicago, IL."},{"key":"10.1016\/j.yebeh.2022.108994_b0415","series-title":"Cognition and reality: principles and implications of cognitive psychology","author":"Neisser","year":"1976"},{"issue":"1362","key":"10.1016\/j.yebeh.2022.108994_b0420","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1098\/rstb.1997.0151","article-title":"The ecological study of memory","volume":"352","author":"Neisser","year":"1997","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0425","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1037\/a0023961","article-title":"Distinguishing sluggish cognitive tempo from attention-deficit\/hyperactivity disorder in adults","volume":"121","author":"Barkley","year":"2012","journal-title":"J Abnorm Psychol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1076\/1380-3395(200002)22:1;1-8;FT056","article-title":"Adaptive decision making, ecological validity, and the frontal lobes","volume":"22","author":"Goldberg","year":"2000","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2022.108994_b0435","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1207\/s15326942dn2501&2_8","article-title":"Ecological assessment of executive function in traumatic brain injury","volume":"25","author":"Gioia","year":"2004","journal-title":"Dev Neuropsychol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108994_b0440","first-page":"6","article-title":"Executive function measures for children: a scoping review of ecological validity","volume":"38","author":"Wallisch","year":"2018","journal-title":"OTJR (Thorofare, NJ)"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0445","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","article-title":"Cognitive effects of antiepileptic drugs","volume":"4","author":"Park","year":"2008","journal-title":"J Clin Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0450","doi-asserted-by":"crossref","first-page":"e00958","DOI":"10.1002\/prp2.958","article-title":"In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108994_b0455","doi-asserted-by":"crossref","first-page":"e00959","DOI":"10.1002\/prp2.959","article-title":"In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0460","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.yebeh.2022.108994_b0465","unstructured":"Lundbeck. ONFI\u00ae (clobazam) tablets, for oral use, CIV [prescribing infomration]; ONFI\u00ae (clobazam) oral suspension, CIV [prescribing information]. Deerfield, IL: Lundbeck; December, 2016."},{"issue":"6","key":"10.1016\/j.yebeh.2022.108994_b0470","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1037\/neu0000681","article-title":"Executive functioning rating scales: ecologically valid or construct invalid?","volume":"34","author":"Soto","year":"2020","journal-title":"Neuropsychology"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108994_b0475","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jcpp.12001","article-title":"Practitioner review: do performance-based measures and ratings of executive function assess the same construct?","volume":"54","author":"Toplak","year":"2013","journal-title":"J Child Psychol Psychiatry"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108994_b0480","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1037\/0033-2909.131.4.483","article-title":"Informant discrepancies in the assessment of childhood psychopathology: a critical review, theoretical framework, and recommendations for further study","volume":"131","author":"De Los","year":"2005","journal-title":"Psychol Bull"},{"issue":"12","key":"10.1016\/j.yebeh.2022.108994_b0485","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1474-4422(07)70290-9","article-title":"Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations","volume":"6","author":"Hobart","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108994_b0490","first-page":"12","article-title":"Rating Scales for clinical studies in neurology\u2014challenges and opportunities","volume":"04","author":"Hobart","year":"2008","journal-title":"US Neurology"},{"key":"10.1016\/j.yebeh.2022.108994_b0495","unstructured":"Sullivan J, Lagae L, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (Study 3) [poster]. Paper presented at: American Epilepsy Society 2020; December 4-8, 2020; Virtual."},{"key":"10.1016\/j.yebeh.2022.108994_b0500","unstructured":"Scheffer IE, Devinsky O, Perry MS, Wheless J, Thiele EA, Wirrell E, et al. Efficacy and tolerability of adjunctive FINTEPLA (fenfluramine HCl) in an open-label extension study of Dravet syndrome patients treated for up to 3 years [poster]. Virtual American Epilepsy Society (AES) Annual Meeting, December 4-8, 2020."}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:48:55Z","timestamp":1761504535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022004437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":100,"alternative-id":["S1525505022004437"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108994","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 UCB. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108994"}}